A clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics designed to silence disease-causing genes. Its pipeline focuses on cardiovascular, hematologic, and rare diseases using proprietary siRNA delivery platforms, and the company has pursued partnerships with larger ph...
No congressional trades have been disclosed for Silence Therapeutics plc (SLN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.